Findings

What do systematic reviews say?

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings: risk of intermediate hyperglycaemia (IFG5.6 mmol/L definition) vs normoglycaemia

HR: 0 IRR: 0 OR: 1

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 participants
Low

Summary of findings: risk of intermediate hyperglycaemia (IFG5.6 mmol/L definition) vs normoglycaemia

HR: 1 IRR: 1 OR: 1

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
947 participants
Low

Summary of findings: risk of intermediate hyperglycaemia (IFG5.6 mmol/L definition) vs normoglycaemia

HR: 8 IRR: 10 OR: 21

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
9017 participants
Low

Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) vs normoglycaemia

HR: 5 IRR: 2 OR: 7

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
1054 participants
Low

Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) vs normoglycaemia

HR: 4 IRR: 4 OR: 7

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
1736 participants
Low

Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) vs normoglycaemia

HR: 0 IRR: 0 OR: 1

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 participants
Low

Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) vs normoglycaemia

HR: 0 IRR: 0 OR: 0

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 participants
Low

Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) vs normoglycaemia

HR: 9 IRR: 6 OR: 15

1 finding from 1 review

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
2818 participants
Low

Summary of findings table 3: comparison of operation types: firebreak skin grafting vs z‐plasty closure of fasciectomy

PEM hand function score at 3 years Major outcome group 1 (hand function) (scores between 0 and 77, where 0 represents no impairment in hand function and 77 represents maximum impairment in hand function) · 79 participants (Ullah 2009)

1 finding from 1 review

Surgery for Dupuytren's contracture of the fingers 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Low

Summary of findings table 3: comparison of operation types: firebreak skin grafting vs z‐plasty closure of fasciectomy

Major outcome group 2 (patient satisfaction and other PROM) · 79 participants (Ullah 2009)

The review found no eligible studies for this question.

1 finding from 1 review

Surgery for Dupuytren's contracture of the fingers 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table 3: comparison of operation types: firebreak skin grafting vs z‐plasty closure of fasciectomy

Correction of MCPJ and PIPJ deformities at 2 weeks Major outcome group 3 (early angular outcomes) · 79 participants (Ullah 2009)

1 finding from 1 review

Surgery for Dupuytren's contracture of the fingers 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Low

Summary of findings table 3: comparison of operation types: firebreak skin grafting vs z‐plasty closure of fasciectomy

Progressive contracture by 3 years Major outcome group 4 (recurrence) · 79 participants (Ullah 2009)

1 finding from 1 review

Surgery for Dupuytren's contracture of the fingers 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Low

Summary of findings table 3: comparison of operation types: firebreak skin grafting vs z‐plasty closure of fasciectomy

Hypoaesthesia Major outcome group 5 (adverse effects) · 79 participants (Ullah 2009)

1 finding from 1 review

Surgery for Dupuytren's contracture of the fingers 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Low

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Survival · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
High

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 599 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 578 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 603 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found